Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesKunming Medical University

China Registration ClassN/A

Develop Information

Active CompaniesKunming Medical University

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A